Long Hauler's is a "heterogenous" syndrome.. few people present the same symptoms, severity, and underlying molecular dysfunction. There absolutely should be a PII; there needs to be in order to see what biomarkers are out there, which ones respond to LLMab, and select for those in the PIII. They went with 50 bc it would nearly insta-fill, I'm assuming (recalling how they had inquiries above the previous 100 total size).

LH isn't going anywhere.. I think this is the most prudent strategy, would have been better to start earlier but we have so many trials going already, they may have thought, based on what the DSMB had said, that CD12 would have a good shot at EUA at least, and waited.